Home LiteratureArticle Details
PMID: 7603979 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection.

Seung LP, Rowley DA, Dubey P, Schreiber H

Abstract

During tumor progression, variants may arise that grow more vigorously. The fate of such variants depends upon the balance between aggressiveness of the variant and the strength of the host immunity. Although enhancing host immunity to cancer is a logical objective, eliminating host factors necessary for aggressive growth of the variant should also be considered. The present study illustrates this concept in the model of a spontaneously occurring, progressively growing variant of an ultraviolet light-induced tumor. The variant produces chemotactic factors that attract host leukocytes and is stimulated in vitro by defined growth factors that can be produced or induced by leukocytes. This study also shows that CD8+ T-cell immunity reduces the rate of tumor growth; however, the variant continues to grow and kills the host. Treatment with a monoclonal anti-granulocyte antibody that counteracts the infiltration of the tumor cell inoculum by non-T-cell leukocytes did not interfere with the CD8+ T-cell-mediated immune response but resulted in rejection of the tumor challenge, indicating a synergy between CD8+ T-cell-mediated immunity and the inhibition of paracrine stimulation.

MeSH Terms
Animals Ascitic Fluid/immunology Bone Marrow/immunology,pathology CD8-Positive T-Lymphocytes/immunology Cytotoxicity, Immunologic Genetic Variation Growth Substances/biosynthesis,physiology Immunity, Cellular Leukocytes/immunology Lymphocytes, Tumor-Infiltrating/immunology,pathology Mice Mice, Inbred BALB C Mice, Inbred C3H Mice, Nude Neoplasms, Radiation-Induced/immunology,pathology T-Lymphocytes/immunology T-Lymphocytes, Cytotoxic/immunology Time Factors Tumor Cells, Cultured Ultraviolet Rays
Chemicals
Growth Substances
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Seung L P
Department of Pathology, University of Chicago, IL 60637, USA.
Rowley D A
Dubey P
Schreiber H
References (28)
28 references, click to expand
  1. Tumor-associated macrophages.
    Curr Opin Immunol. 1989-1990;2(5):689-92 PMID: 2701968
  2. Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance.
    Cancer Res. 1990 Jul 1;50(13):3851-8 PMID: 2112981
  3. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity.
    J Exp Med. 1990 Oct 1;172(4):1217-24 PMID: 2212951
  4. Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells.
    J Immunol. 1991 Jul 1;147(1):22-8 PMID: 1711076
  5. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4.
    Cell. 1992 Dec 24;71(7):1093-102 PMID: 1335364
  6. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA.
    Science. 1993 Jan 1;259(5091):94-7 PMID: 8418502
  7. Modulation of in vivo immune response by selective depletion of neutrophils using a monoclonal antibody, RP-3. I. Inhibition by RP-3 treatment of the priming and effector phases of delayed type hypersensitivity to sheep red blood cells in rats.
    J Immunol. 1993 May 1;150(9):3728-38 PMID: 8473729
  8. Modulation of in vivo immune response by selective depletion of neutrophils using a monoclonal antibody, RP-3. II. Inhibition by RP-3 treatment of mononuclear leukocyte recruitment in delayed-type hypersensitivity to sheep red blood cells in rats.
    J Immunol. 1993 May 1;150(9):3739-46 PMID: 8473730
  9. Abrogation of tumor-inhibitory MRC-OX8+ (CD8+) effector T-cell generation in rats by selective depletion of neutrophils in vivo using a monoclonal antibody.
    Int J Cancer. 1993 Apr 22;54(1):131-6 PMID: 8478140
  10. CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help.
    J Exp Med. 1993 Jun 1;177(6):1791-6 PMID: 7684435
  11. A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target.
    J Exp Med. 1993 Sep 1;178(3):933-40 PMID: 8394406
  12. Neutrophils are essential for early anti-Listeria defense in the liver, but not in the spleen or peritoneal cavity, as revealed by a granulocyte-depleting monoclonal antibody.
    J Exp Med. 1994 Jan 1;179(1):259-68 PMID: 8270870
  13. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors.
    Cancer Res. 1994 Apr 15;54(8):2218-22 PMID: 8174129
  14. Inhibition of tumor growth by elimination of granulocytes.
    J Exp Med. 1995 Jan 1;181(1):435-40 PMID: 7807024
  15. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host.
    Cancer Res. 1960 Dec;20:1561-72 PMID: 13756652
  16. Antigenicity of murine skin tumors induced by ultraviolet light.
    J Natl Cancer Inst. 1974 Nov;53(5):1333-6 PMID: 4139281
  17. Production of specific macrophage activating factor by lymphocytes from tumor-bearing mice.
    Cell Immunol. 1977 May;30(2):341-52 PMID: 67910
  18. Lymphocyte cytotoxicity against autologous tumour biopsy cells in humans.
    Int J Cancer. 1977 Oct 15;20(4):512-9 PMID: 914394
  19. Properties of rat anti-MHC antibodies produced by cloned rat-mouse hybridomas.
    Immunol Rev. 1979;47:91-115 PMID: 398328
  20. Separation and characteristics of tumor-infiltrating lymphocytes in man.
    Contemp Top Immunobiol. 1980;10:79-107 PMID: 6967801
  21. Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells.
    J Exp Med. 1984 May 1;159(5):1295-311 PMID: 6232335
  22. Loss of growth factor dependence and conversion of transforming growth factor-beta 1 inhibition to stimulation in metastatic H-ras-transformed murine fibroblasts.
    Cancer Res. 1988 Dec 15;48(24 Pt 1):6999-7003 PMID: 3056609
  23. Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells.
    J Exp Med. 1989 Jul 1;170(1):217-32 PMID: 2787379
  24. Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity.
    Proc Natl Acad Sci U S A. 1989 Dec;86(23):9456-60 PMID: 2512580
  25. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response.
    Cell. 1990 Feb 9;60(3):397-403 PMID: 2137372
  26. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance.
    Proc Natl Acad Sci U S A. 1990 Feb;87(4):1486-90 PMID: 2137615
  27. Immunotherapy of cancer using local administration of lymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2.
    Immunol Lett. 1990 Feb;23(4):287-92 PMID: 2347603
  28. Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory.
    J Immunol. 1990 Nov 1;145(9):3136-43 PMID: 2212677
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
0027-8424
Published
1995-07-03
Pages
6254-8
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC41496
Subset
IM
Grants
NCI NIH HHS · P01 CA-19266 · United States
NCI NIH HHS · R01 CA-37156 · United States
NCI NIH HHS · R37 CA-22677 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]